Aim 4 Sample Clauses

Aim 4. The Division of Biostatistics, the Core, and the PSMG provide support for this goal.
Sample 1
AutoNDA by SimpleDocs
Aim 4. Xx. Xxxxxxxxx with the Core staffare developing new educational programs for the C/T community including monthly biostatistics clinics and weekly roundtable sessions. Core faculty and staff are now attending presentations of the PSMG and the Division of Biostatistics.The Ph.D. program in Biostatistics currently has 7 students that have completed their first year of studies, and we are in the process of accepting 3applicants for the next cohort..A suite of advanced courses (6 in total) are currently being developed for next school year, including Bayesian Data Analysis and Bayes Computing, Statistical Analysis of Clinical Trials, High Performance Computing, Advanced Statistical Theory, Spatial Data Analysis and Advanced Survival Analysis.
Sample 1
Aim 4. Quantitative health disparities research is a growing field and we anticipate that the proposed Center will allow UM to further deepenour foothold in this arena. We will look to formalize quantitative health disparities research and education by producing research papers, developing new software modules for wider usage of methods that we will develop and developing new training programs relating to issues in quantitative health disparities research. We will begin building our curriculum based on our plans in the already submitted T32 training grant application in quantitative epidemiology and biostatistics with a slant towards quantitative health disparities.
Sample 1
Aim 4 i. Obtained Research Cabinet approval for IRBShare and worked with RIM, Human Subject Research Office, and legal counsel to adopt and sign contract for it.
Sample 1
Aim 4. To create mentoring programs that maximize advancing trainees toward academic careers through: (a) intensive mentoring, (b) close monitoring of trainee progress and (c) implementing retention strategies; and (d) tracking and evaluating the quality and outcomes of the graduates of these programs
Sample 1
Aim 4. To determine whether methylphenidate treatment for ADHD is associated with a statistically significant increase in long-term (> 1 year) risk of negative effects on: the rate of growth (i.e. height and weight) and of pubertal maturation. According to international guidelines, treatment for ADHD is based on a multimodal approach that combines behavioural and pharmacological treatment.52,53,12 The first choice medication for ADHD and the most frequently used treatment for ADHD in Europe is methylphenidate.36 Positive effects of stimulants are supported by numerous studies with clear improvements in the core symptoms of hyperactivity, impulsivity and inattention.54 However, these improvements can be accompanied by common mild and transient different side effects (sleeplessness, nervousness, reduced appetite, headache, abdominal pain, changes in blood pressure and heart rate) and several less common effects including reduced weight gain and growth reduction with prolonged use.55,56,57 Although many studies have monitored changes in growth and weight during medication, they have not provided definite results as to whether the reported growth and weight suppression are caused by medication or not. Such effects on growth are usually reported as minor, but there is substantial variability with some children being completely unaffected58,59,60 and others reporting significant growth suppression.35,61,62,63 There are many methodological limitations with these published studies and as a consequence it has not been possible to draw firm conclusions and poor growth has therefore remained a common public concern about the treatment of ADHD. Considering these gaps in our understanding and those expressed by the European Medicine Agency that we need more data about the long term effects of methylphenidate, the ADDUCE programme aimed to address scientific questions about the potential long term ("more than 1 year") adverse effects of Methylphenidate on growth and pubertal maturation in ADHD children and adolescents. The primary objective of the study, aimed to investigate the possible developmental adverse effects by stimulant medication in the long term has been achieved by a broad programme of work including: 1. A systematic review of evidence in the published literature: a systematic review has been performed and extensively updated up to August 2015 on the human literature focusing on the impact on growth and pubertal maturation of chronic MPH and stimulants exposure in...
Sample 1
Aim 4. To determine the role of the ASFMR1-encoded protein in fragile X syndrome ASFMR1, an antisense gene overlapping the FMR1 locus, has been proposed to play a role in the etiology of fragile X syndrome, possibly due to the absence of the ASFMR1-encoded protein. To determine if the ASFMR1 protein is essential for normal cognitive function, we looked for sequence variants in both developmentally delayed and control males that would alter the function of the ASFMR1 protein. This application of the dataset generated in Aim 3 extended our findings to a second candidate gene for intellectual disability.
Sample 1
AutoNDA by SimpleDocs

Related to Aim 4

  • CFR 200 328. Failure to submit such required Performance Reports may cause a delay or suspension of funding. 30 ILCS 705/1 et seq.

  • Year 2000 Compatibility Take all action necessary to assure that its computer based systems are able to operate and effectively process data including dates on and after January 1, 2000, and, at the reasonable request of the Administrative Agent or the Required Lenders, provide evidence to the Lenders of such year 2000 compatibility.

  • Yours sincerely Xxxxxx Xxxxx

  • Xxxxx, Haldimand, Norfolk An employee shall be granted five working days bereavement leave with pay upon the death of the employee’s spouse, child, stepchild, parent, stepparent, legal guardian, grandchild or step-grandchild.

  • FIPPA The HSP acknowledges that the LHIN is bound by FIPPA and that any information provided to the LHIN in connection with this Agreement may be subject to disclosure in accordance with FIPPA.

  • Per-pupil Funding The School's non-facility general fund per-pupil funding shall be as defined in Sec. 302D-28, HRS. The Commission shall distribute the School's per-pupil allocation each fiscal year pursuant to Sec. 302D-28(f), HRS, and shall provide the School with the calculations used to determine the per-pupil amount each year. All funds distributed to the School from the Commission shall be used solely for the School's educational purposes as appropriated by the Legislature, and the School shall have discretion to determine how such funding shall be allocated at the school level to serve those purposes subject to applicable laws and this Contract.

  • Sincerely, Xxxxxxx Xxxxxx,

  • COVID-19 Employees of Contractor and/or persons working on its behalf, including, but not limited to, subcontractors (collectively, “Contractor Personnel”), while performing services under this Agreement and prior to interacting in person with City employees, contractors, volunteers, or members of the public (collectively, “In-Person Services”) must be fully vaccinated against the novel coronavirus 2019 (“COVID-19”). “Fully vaccinated” means that 14 or more days have passed since Contractor Personnel have received the final dose of a two-dose COVID-19 vaccine series (Moderna or Pfizer-BioNTech) or a single dose of a one-dose COVID-19 vaccine (Xxxxxxx & Xxxxxxx/Xxxxxxx) and all booster doses recommended by the Centers for Disease Control and Prevention. Prior to assigning Contractor Personnel to perform In-Person Services, Contractor shall obtain proof that such Contractor Personnel have been fully vaccinated. Contractor shall retain such proof for the document retention period set forth in this Agreement. Contractor shall grant medical or religious exemptions (“Exemptions”) to Contractor Personnel as required by law. If Contractor wishes to assign Contractor Personnel with Exemptions to perform In- Person Services, Contractor shall require such Contractor Personnel to undergo weekly COVID-19 testing, with the full cost of testing to be borne by Contractor. If Contractor Personnel test positive, they shall not be assigned to perform In-Person Services or, to the extent they have already been performing In-Person Services, shall be immediately removed from those assignments. Furthermore, Contractor shall immediately notify City if Contractor Personnel performing In-Person Services (1) have tested positive for or have been diagnosed with COVID-19, (2) have been informed by a medical professional that they are likely to have COVID-19, or (3) meet the criteria for isolation under applicable government orders.

  • NO HARDSTOP/PASSIVE LICENSE MONITORING Unless an Authorized User is otherwise specifically advised to the contrary in writing at the time of order and prior to purchase, Contractor hereby warrants and represents that the Product and all Upgrades do not and will not contain any computer code that would disable the Product or Upgrades or impair in any way its operation based on the elapsing of a period of time, exceeding an authorized number of copies, advancement to a particular date or other numeral, or other similar self-destruct mechanisms (sometimes referred to as “time bombs,” “time locks,” or “drop dead” devices) or that would permit Contractor to access the Product to cause such disablement or impairment (sometimes referred to as a “trap door” device). Contractor agrees that in the event of a breach or alleged breach of this provision that Authorized User shall not have an adequate remedy at law, including monetary damages, and that Authorized User shall consequently be entitled to seek a temporary restraining order, injunction, or other form of equitable relief against the continuance of such breach, in addition to any and all remedies to which Authorized User shall be entitled.

  • Information Technology Enterprise Architecture Requirements If this Contract involves information technology-related products or services, the Contractor agrees that all such products or services are compatible with any of the technology standards found at xxxxx://xxx.xx.xxx/iot/2394.htm that are applicable, including the assistive technology standard. The State may terminate this Contract for default if the terms of this paragraph are breached.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!